Mohammadreza Shoghli

Mr. Mohammadreza Shoghli

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MSMohammadreza Shoghli
Mohammadreza Shoghli
A. Inkeri LokkiA. Inkeri Lokki
A. Inkeri Lokki
MLMitja Lääperi
Mitja Lääperi
JSJuha Sinisalo
Juha Sinisalo
MLMarja-Liisa Lokki
Marja-Liisa Lokki
RLReijo Laaksonen
Reijo Laaksonen
Ceramides and other sphingolipids are implicated in vascular dysfunction and inflammation. They have been suggested as potential biomarkers for hypertension. However, their specific association with hypertension prevalence and onset requires further investigation. This study aimed to identify specific ceramide and phosphatidylcholine species associated with hypertension prevalence and onset. The 2002 FINRISK (Finnish non-communicable risk factor survey) study investigated the association between coronary event risk scores (CERT1 and CERT2) and hypertension using prevalent and new-onset hypertension groups, both consisting of 7722 participants, over a span of 10 years. Ceramide and phosphatidylcholine levels were measured using tandem liquid chromatography-mass spectrometry. Ceramide and phosphatidylcholine ratios, including ceramide (d18:1/18:0), ceramide (d18:1/24:1), phosphatidylcholine (16:0/16:0), and the ratio of ceramide (d18:1/18:0)/(d18:1/16:0), are consistently associated with both prevalence and new-onset hypertension. Ceramide (d18:1/24:0) was also linked to both hypertension measures. Adjusting for covariates, CERT1 and CERT2 showed no-longer-significant associations with hypertension prevalence, but only CERT2 predicted new-onset hypertension. Plasma ceramides and phosphatidylcholines are crucial biomarkers for hypertension, with imbalances potentially contributing to its development. Further research is needed to understand the underlying mechanisms by which ceramides will contribute to the development of hypertension.

12 March 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
MSMohammadreza Shoghli
Mohammadreza Shoghli
JSJuha Sinisalo
Juha Sinisalo
ALA. Inkeri Lokki
A. Inkeri Lokki
MLMitja Lääperi
Mitja Lääperi
MLMarja-Liisa Lokki
Marja-Liisa Lokki
RLReijo Laaksonen
Reijo Laaksonen
Objectives This study aimed to explore the association between lipid-based Cardiovascular Event Risk Tests (CERT1 and CERT2), including ceramides (Cer) and phosphatidylcholine (PC) lipid species, and rheumatoid arthritis (RA), an inflammatory disease that can increase the risk of cardiovascular diseases. Design Prospective population-based cohort study. Setting Primary care centres across five geographical areas in Finland. Methods The study included 7702 individuals (selected from the FINRISK cohort) who were assessed for the prevalence and incidence of RA. At baseline, the cohort included 7518 RA-free individuals, among whom 329 developed RA during the study, and 184 had a history of RA at baseline. Serum levels of ceramides and PC were measured using mass spectrometry, and CERT scores were calculated. Main outcome measures Prevalence and incidence of RA, CERT scores, and serum lipid levels. Results CERT scores were associated with prevalent RA but not with incident RA in the full cohort. Adjusted ORs and 95% CI for prevalent RA were 1.24 (95% CI 1.05 to 1.46) for CERT1 and 1.42 (95% CI 1.20 to 1.68) for CERT2. Stratified analyses showed that these associations were consistent among individuals over 50 years of age and across both sexes. The Cer (d18:1/16:0)/PC (16:0/22:5) ratio was significantly associated with RA in younger individuals (OR 1.66; 95% CI (1.26 to 2.18)). Overall, the association between lipids and RA was stronger in women than men. Conclusions The study shows a significant association between prevalent RA and bioactive lipid species used for cardiovascular risk assessment. These findings emphasise the importance of considering residual inflammatory risks, such as RA, in cardiovascular risk evaluations in clinical settings.

28 July 2025 in Diabetes Asia Journal
Verified
Journal Article
Closed access
SHSiyamak Jalal Hosseini
Siyamak Jalal Hosseini
MSMohammadreza Shoghli
Mohammadreza Shoghli
HFHermon Eyob Fesseha
Hermon Eyob Fesseha
YEYosan Eyob
Yosan Eyob
Right ventricular infarction (RVI) is a life-threatening complication of inferior ST-elevation myocardial infarction (STEMI), occurring in approximately 30–50% of such cases—typically when the proximal right coronary artery (RCA) is occluded [1,2]. While left ventricular (LV) infarction receives more clinical focus, RVI significantly worsens patient outcomes and is often underdiagnosed due to nonspecific signs [3,4]. The right ventricle (RV) is anatomically distinct from the LV, with a thinner free wall, lower systolic pressure, and greater dependence on preload. These characteristics make the RV highly susceptible to ischemic damage and volume depletion. RV dysfunction can compromise left-sided output due to interventricular dependence, thereby leading to systemic hypotension and cardiogenic shock [5,6]. Although timely revascularization is the cornerstone of STEMI therapy, standard management strategies may be inadequate in dominant RVI. In such cases, mechanical support such as right ventricular assist devices (RVADs) or extracorporeal membrane oxygenation (ECMO) can be lifesaving. Unfortunately, these are not universally accessible, particularly in resource-limited settings [7]. We present a case of inferior STEMI with RVI, highlighting the limitations of current management and the impact of unavailable mechanical RV support.

28 July 2025 in Diabetes Asia Journal
Verified
Journal Article
Closed access
HFHermon Eyob Fesseha
Hermon Eyob Fesseha
MSMohammadreza Shoghli
Mohammadreza Shoghli
LSLaura Sundell
Laura Sundell
MAMari Ala-Houhala
Mari Ala-Houhala
AHAlexandra Häme
Alexandra Häme
YEYosan Eyob
Yosan Eyob
Background: Reactive arthritis (ReA) is an inflammatory joint condition that typically develops days to weeks after a gastrointestinal or genitourinary infection. While it is often associated with a classic triad of arthritis, urethritis, and conjunctivitis, many patients may not exhibit all three symptoms. Previously known as “Reiter syndrome,” named after Hans Reiter, ReA is thought to result from an abnormal autoimmune response to infections caused by pathogens such as Salmonella, Shigella, Campylobacter, or Chlamydia. Recognizing this connection is essential for effective diagnosis and treatment. Case Description: A 67-year-old male developed reactive arthritis (ReA) following intravesical Bacillus Calmette-Guérin (iBCG) therapy for non-muscle invasive bladder cancer. Elevated inflammatory markers and a negative HLA-B27 result were noted. The symptoms were attributed to iBCG-related ReA, leading to the discontinuation of iBCG treatment. Outcome: Initial treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids was ineffective, necessitating disease-modifying antirheumatic drugs (DMARDs) for sustained remission and symptom control. Although chronic arthritis requiring prolonged DMARD therapy is uncommon, the patient required over 1.5 years of DMARD treatment to manage symptoms effectively. Keywords: iBCG intravesical Bacillus Calmette-Guérin, DMARD disease-modifying antirheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs

28 December 2024 in Diabetes Asia Journal
Verified
Journal Article
Closed access
HFHermon Eyob Fesseha
Hermon Eyob Fesseha
LSLaura Sundell
Laura Sundell
TLTeemu Laakso
Teemu Laakso
YEYasan Eyob
Yasan Eyob
MSMohammadreza Shoghli
Mohammadreza Shoghli
Rajesh JainRajesh Jain
Rajesh Jain
Background: Post-cardiac injury syndrome (PCIS) is an inflammatory condition triggered by immune responses following cardiac injury. PCIS encompasses post-myocardial pericarditis, post-pericardiotomy syndrome (PPS), and post-traumatic pericarditis, whether iatrogenic or not. In this case report, we describe a patient who developed PPS after undergoing mitral valve replacement surgery. Case presentation: A young African woman with mitral stenosis caused by rheumatic fever underwent successful mitral valve replacement surgery. Approximately one month later, she developed post-pericardiotomy syndrome, which was subsequently diagnosed and treated. The patient initially presented to the hospital with exertional dyspnoea, and echocardiography revealed severe mitral stenosis, leading to the scheduling of surgery. While awaiting the procedure, she developed atrial fibrillation (AF) and congestive heart failure. In 2022, she underwent mitral valve replacement surgery and was discharged one week later after experiencing a smooth recovery. Two weeks after discharge, she visited the emergency department due to shortness of breath, but no concerning signs were found upon examination. She was prescribed diuretics and discharged. One week later, she was admitted to the hospital again due to chest pain, dyspnoea, and an elevated C-reactive protein (CRP) level of 123. Echocardiography and chest computed tomography (CT) scans were normal. She was treated with antibiotics under suspicion of pneumonia and subsequently discharged. Ten days later, she returned to the emergency department with high fever, chest pain, and dyspnea, and her CRP level had risen to 240. Echocardiography revealed no signs of endocarditis or pericardial effusion. Considering the patient's surgical history and frequent hospitalizations for similar symptoms, PPS was suspected. The patient was administered a first-line treatment of colchicine 0.5mg once a day. As a result, CRP levels decreased, fever and chest pain resolved, and she was discharged in a stable condition. A month later she was re-admitted to the hospital due to PPS relapse, Colchicine dose was elevated to 1mg a day and was discharged in good condition. Colchicine was planned to be continued for six months. Conclusion: PPS is a common complication following open-heart surgery, characterized by a generally mild course but with the potential for severe complications. Treatment typically involves anti-inflammatory agents, aspirin, and colchicine. The recurrence rate is approximately 10-15%. Early diagnosis and treatment of PPS can minimize frequent hospitalizations and reduce the need for extensive testing